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Background: Fibromyalgia (FM) is a syndrome most prevalent in women, in whom it is characterized mainly
by chronic pain. An important issue is that many patients with FM are reported to have temporomandibular
dysfunction (TMD), and the coexistence of these pathologies generates a clinical outcome of high complexity. The
literature is unclear regarding an effective therapy for reducing pain in patients with both comorbidities. Exercise
training and phototherapy (low-level laser therapy with light-emitting diode) are two of the approaches used to
treat pain. Thus, the aim of this study is to assess the potential role of exercise training plus phototherapy in
reducing chronic pain in women with FM and TMD. A further aim is to determine whether the interventions can
improve quality of life and modulate endogenous serotonin.
Methods/Design: A randomized controlled clinical trial will be conducted. It will involve 60 women ≥ 35 years of
age with a diagnosis of FM and TMD. After recruitment, patients will be randomly allocated to one of four groups:
a control group (no intervention), a group that will receive a phototherapy intervention (PHO), a group that will be
prescribed muscle-stretching, aerobic, and facial exercises (EXT), or a group that will receive phototherapy plus
exercise interventions (PHO + EXT). The trial will last 10 weeks, and the following outcomes will be evaluated on
two separate occasions (baseline and within 24 h after the last day of the protocol). Pain intensity will be analyzed
using a visual analogue scale and the McGill Pain Questionnaire, and pain thresholds will be punctuated using a
digital algometer. FM symptoms will be assessed using the Fibromyalgia Impact Questionnaire, and quality of life
will be determined with the 36-item Short Form Health Survey. Serotonin levels will be evaluated in salivary samples
using a competitive enzyme-linked immunosorbent assay.
Discussion: This is the first randomized controlled trial in which the role of phototherapy, exercise training, and a
combination of these interventions will be evaluated for chronic pain in patients with FM and TMD. The results will
offer valuable clinical evidence for objective assessment of the potential benefits and risks of procedures.
Trial registration: ClinicalTrials.gov Identifier: NCT02279225. Registered 27 October 2014.
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Fibromyalgia (FM) is a chronic syndrome characterized
mainly by pain, nonrestorative sleep, fatigue, morning
stiffness, depression, and cognitive disorders [1, 2].
Patients with FM often show widespread pain in the
presence of tender points (expressed as mild or greater
tenderness), which provide the most sensitive, specific,
and accurate criteria for making the diagnosis [1, 3].
Using this classification, almost all patients with FM are
women because they have more tender points than do
men [4]. Overall, FM symptoms lead to significant re-
duction in functional capacity and quality of life [2, 5, 6].
Developing treatment teams is useful, including clini-
cians with expertise in patient education, exercise
training interventions, and cognitive behavioral ther-
apy [7–9]. An optimized treatment can be provided
using the following steps: (1) overall recommendation
(e.g., patient education), (2) nonpharmacologic (e.g.,
exercise, cognitive behavioral therapy, alternative medicine,
and central nervous system neurostimulatory intervention),
and (3) pharmacologic (e.g., tricyclic complexes, gaba-
pentinoids, γ-hydroxybutyrate, naltrexone, cannabinoids,
selective serotonin reuptake antagonists, nonsteroidal
anti-inflammatory drugs, and opioids) [4].
A key issue is the association of FM with other mus-
culoskeletal comorbidities, such as temporomandibular
dysfunction (TMD) [5]. It has been shown that TMD
can develop as a result of mandibular compression dur-
ing daily living activities and sleep in the patients with
FM [5–7], in which the coexistence of these pathologies
generates a clinical outcome of high complexity [8]. Un-
fortunately, no published studies of patients with FM
and TMD have evaluated an effective pharmacologic
and/or nonpharmacologic therapeutic intervention. Pre-
vious studies have examined only the role of different
interventions in the situation of a pathology per se. In
this issue, exercise training is highly recommended in
the controlling of patients with FM. Aerobic, strength,
and mixed training programs (combination of aerobic,
strength, and flexibility) were shown to reduce pain, num-
ber of tender points, fatigue, depression, and anxiety and
to improve health-related quality of life as well as func-
tional capacity [9, 10]. Exercises targeted for the face are
also indicated for treatment of TMD as a procedure com-
bined with other therapies (e.g., electrotherapy, physio-
therapy, temporomandibular joint mobilization, and facial
massage) to improve pain sensitivity [11–13].
Phototherapy, such as low-level laser therapy (LLLT)
and light-emitting diode (LED) therapy, are recently
developed options to treat FM and TMD [14]. LLLT is
assumed to modulate several signaling pathways and
physiologic mechanisms involved in analgesia [15–17].
This therapeutic approach seems to increase β-endorphin
levels, lymphatic flow, and blood supply. Moreover, LLLTis reported to reduce bradykinin, histamine release, swell-
ing, pain-associated molecules, and inflammation phase
and to induce muscle relaxation [18, 19]. Similar results
have been shown with LED therapy, which has a minor
cost and better equipment durability [20].
A comprehensive review of the literature revealed no
studies evaluating the role of phototherapy with multiple
light sources (LLLT and LED) on the same device in the
pain condition in patients with FM and TMD. In
addition, there are no prior data involving a combined
intervention of phototherapy and exercise training in pa-
tients with FM and TMD. The hypothesis of the pro-
posed study is that combined intervention is capable of
improving chronic pain in patients with FM and TMD.
Knowledge regarding the clinical effects of these inter-
ventions can contribute to improved rehabilitation and
quality of life among such patients.
Objective
In this trial, we seek to assess the potential role of exer-
cise training plus phototherapy to reduce chronic pain
in women with FM and TMD.
Methods/Design
Study design
The EXTRAPHOTO trial (ClinicalTrials.gov identifier
NCT02279225) is a multicenter randomized controlled
clinical trial comparing the use of exercise training,
phototherapy, and exercise training plus phototherapy
for pain control in women with two comorbidities (FM
and TMD). As part of a simultaneous recruitment
process, in the EXTRAPHOTO trial we will identify
participants with target disorders in a database of the
Unified Health System of Sao Paulo, Brazil. A prelimin-
ary analysis showed that patients at three centers with
FM specialties are eligible: (1) the Rheumatology Clinic
of Nove de Julho University, Sao Paulo, Brazil; (2) the
basic health center of Sao Paulo, Brazil; and (3) the basic
health center of Sao Paulo in Sao Bernardo do Campo,
Brazil. The study procedure will follow the guidelines of
the Consolidated Standards of Reporting Trials state-
ment. All participants will receive data on the study aims
and experimental procedures. We will obtain signed,
written informed consent forms from each patient be-
fore inclusion in the study. The trial scheme is detailed
in Fig. 1.
Population and sample size
In a literature review, we found that FM prevalence is
higher in women between ages 35 and 60 years than in
men [21]. All women patients aged ≥ 35 years and re-
ferred for FM and TMD diagnostic evaluation were eli-
gible for inclusion in the present trial. Patient eligibility
comprises an evaluation of medical history, physical
Fig. 1 Trial scheme. CON, Control; EXT, Exercise training; PHO + EXT, Phototherapy plus exercise training; PHO, Phototherapy
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evaluations. Moreover, patients had to have undergone
FM screening as reported by the American College of
Rheumatology using the Fibromyalgia Impact Question-
naire (FIQ) 1. The TMD diagnosis had to be reported on
the basis of TMD research diagnostic criteria (axes I and
II) [22]. The sample size calculation was based on a pre-
vious study by Consalter et al. [23] in which the TMD
prevalence was 80 % in patients with FM. A 95 % reli-
ability and a 10 % error rate was assumed to estimate











A total of 60 women will be randomized for this trial,
with 20 women allocated per group.
Recruitment and inclusion criteria
The recruitment methods include direct referral of pa-
tients who consult for FM, in which TMD also will be
investigated. A rheumatologist and a dentist will make
the diagnoses of FM and TMD, respectively. A physicianat each FM medical center will participate. A compatible
diagnosis of FM will be obtained on the basis of evalu-
ation criteria similar to those previously well defined
[25]. The recruitment of 60 patients is planned to be
finished within 24 months. Inclusion criteria are as
follows: women ≥ 35 years of age presenting with at least
a 5-year diagnosis of FM and TMD, optimized drug
treatment, cognitive independence to respond to inquir-
ies, functionally independent regarding daily physical ac-
tivity, availability and ability to fully comply with the
training process and phototherapy, and no contraindica-
tion to the research procedures. All centers will be in-
formed about the EXTRAPHOTO trial and its inclusion
criteria during department meetings. Exclusion criteria
are patients in a prior regular and structured physical ac-
tivity program; missing more than three times from
treatment; presence of psychiatric disorders, missing
teeth, and/or use of dentures; a history of trauma to the
face; currently undergoing orthodontic intervention; and
any contraindication to exercise or phototherapy. The
FM symptoms can be confused with other disorders.
Thus, women for whom there are suspicions of any of
the following disorders will be excluded: osteoarthritis,
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rheumatism, polymyalgic rheumatic disease, hydroxy-
apatite crystal diseases, systemic lupus erythematous,
dermatomyositis-polymyositis complex, Lyme disease,
hypothyroidism or hyperthyroidism, hyperparathyroid-
ism, previous history of hepatitis, and history for
Epstein-Barr virus infection. Sjögren, McArdle, Addison,
Cushing, and paraneoplastic syndromes will also be exclu-
sion criteria.
Randomization, blinding, and experimental groups
The EXTRAPHOTO trialists will enroll patients imme-
diately after diagnosis of the two comorbidities and re-
ferral from recruitment centers. Patient enrollment and
randomization, as well as data management, will be car-
ried out by the Program in Biophotonics Applied to
Health Sciences of the Nove de Julho University. The
blinding will be applied to patients receiving photother-
apy and a researcher reported to guide the exercise
training. Thus, a researcher will be responsible for pro-
gramming the phototherapy device, which can be turned
on (phototherapy) or off (placebo) prior to application
based on the randomization. A second researcher will
guide the exercise training and will be blinded for photo-
therapy and/or placebo procedures. A third investigator
will be blinded to allocation and will independently
assess the outcomes. The statistical analysis will be per-
formed by a fourth researcher, who will also be blinded
to allocation of the patients.
The eligible participants will be instructed not to
change their lifestyle or pharmacologic therapy during
the study and will be randomized to one of the following
groups:
1. Control (CON): patients not subjected to any
intervention; the phototherapy device will be turned
off (placebo) as a blinded procedure for these
participants
2. Phototherapy (PHO): patients subjected to
phototherapy
3. Exercise training (EXT): patients subjected to
aerobic exercise; the phototherapy device will be
turned off (placebo) as a blinded procedure for these
participants
4. Phototherapy plus exercise training (PHO + EXT):
patients subjected to phototherapy and aerobic
exercise training
Interventions
The trial will be 10 weeks long, during which time
patients will undergo two sets of phototherapy, exercise,
or placebo procedures per week. Phototherapy will be
applied 30 min before each exercise bout, and treatment
sessions will be carried out Tuesdays and Thursdayseach week. For eligible patients, the research will record
outcome parameters at baseline prior randomization and
48 h after the last day of intervention. This evaluator will
be blinded to the allocation of the patients into the re-
spective groups.
Assessment and result reliability
Two therapists will guide the interventions at each
basic health center. To ensure the feasibility of the
study and the reliability of the results, all therapists
and researchers will be trained in data collection pro-
cedures before the start of the trial. Moreover, the re-
sults will be analyzed by an independent investigator
without knowledge of the allocation of patients to their
experimental groups.
Phototherapy
Phototherapy will be carried out with a PainAway™ nine-
diode cluster portable device (Multi Radiance Medical,
Solon, OH, USA). This portable device was specifically
designed for pain relief and has two operating modes:
mild and severe. Because of the characteristics of pain
that patients with FM, we decided to use the device at
the mild setting. The device has two identical application
hand pieces—one active tip and the other for placebo
procedure without energy, both equipped with a similar
sound device. These equipment pieces are required to
blinding applicator research and patients. Thus, the re-
searcher who will apply phototherapy and the patient
will not know which tip was used (active or placebo).
The irradiation will be applied only in the tender points
in which pain has been reported by the participants.
These tender points can be occipital, cervical (near the C7),
trapezius, supraspinatus, second costochondral joint, lateral
epicondyle and gluteal/sacrum, and greater trochanter on
the medial knee border. The temporomandibular joint
(bilaterally) will be another irradiation target because
of TMD. Each point will be irradiated for 300 s, in
which 39.3 J of total energy will be delivered for each
irradiation point. An independent researcher will be
responsible for controlling the on or off phototherapy
device because therapists and patients will be blinded
to the procedure. The applicator researcher and pa-
tient will be wearing eye protection devices. The CON
group will be subjected to the same procedures as the
groups subjected to the PHO intervention. The photo-
therapy device to be used is shown in Fig. 2. All param-
eters of the phototherapy device are shown in the
Table 1.
Exercise training protocol
The EXT protocol will be carried out according to the
guidelines of the American College of Sports Medicine
[26], and a previously published protocol will be applied
Fig. 2 Phototherapy device that will be used to treat pain
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FM [25]. The protocol consists of stretching and aerobic
exercise two times per week for 10 weeks. Active static
stretching will be applied to the following muscle
groups: biceps, trapezius, latissimus dorsi, pectoralis,Table 1 Phototherapy parameters
Parameters Pulse
1 Superpulsed infrared
Wavelength of lasers (nm) 905
Frequency (Hz) 1000
Average optical output (mW) 0.9
Power density (mW/cm2) 2.25
Peak power (W) 8.5
Dose (J) 0.3
Energy density (J/cm2) 0.75
Spot size of laser (cm2) 0.4
Number of LEDs 4 Red
Wavelength of LEDs (nm) 640 (±10)
Frequency (Hz) 2
Average optical output (mW), each 15
Power density (mW/cm2), each 16.66
Dose (J), each 4.5
Energy density (J/cm2), each 5
Spot size of LED (cm2), each 0.9
Number of LEDs 4 Infrared
Wavelength of LEDs (nm) 875 (±10)
Frequency (Hz) 16
Average optical output (mW), each 17.5
Power density (mW/cm2), each 19.44
Dose (J), each 5.25
Energy density (J/cm2), each 5.83
Spot size of LED (cm2), each 0.9
Magnetic field (mT) 35
Treatment time (s) 300
Aperture of device (cm2) 4
Total energy delivered (J) 39.3
LED light-emitting diodeparaspinal, hamstrings, and quadriceps. Each stretching
exercise will be performed three times for 30 s, and 30 s
of rest will be allowed between each stretch. The stretch
will be conducted to produce mild discomfort. The aer-
obic exercise will be carried out on an electronic motor-
ized drive (LX-150; Movement, Sao Paulo, Brazil)
without inclination for 30 min per session. The exercise
will be guided at an intensity of 75 % of age-predicted
maximum heart rate (220 − age in years).
Exercises for TMD will be carried out as reported in
detail elsewhere [27]. Exercises will be performed with
the patient in a sitting position and repeated three times
for every movement. A maximum oral opening will be
required for the first exercise; the second exercise will be
a tongue slippage on the palate; and the third exercise
will be oral lateralization to the right and left with con-
traction of the masseter muscle. This exercise will be
conducted with the participant’s mouth filled with air for
3 s. Ultimately, circular fingertip motions will be applied
with slight pressure on the temporomandibular joint and
masseter muscle [27, 28].
Outcome parameters
The outcome parameters described below will be evalu-
ated at baseline and 24 h after the last day of the experi-
mental protocol.
Personal and anthropometric data
We will collect data on participants’ occupation, educa-
tion level, marital status, social security number, home
address, age, body weight, and height.
Overall parameters of pain
To assess overall parameters of pain, we will gather in-
formation on daily duration of pain, pain tender points,
number of days with a high pain level, sleep quality,
main features that show accentuation or worsening of
pain, incidence of stiffness and pain, jaw locking, and
morning fatigue.
Visual analogue scale
We will use a visual analogue scale (VAS) to assess
pain level. The VAS consists of a limited strip of
10 cm in length. This strip has at its ends the an-
chor terms no pain and worst pain possible. The pa-
tient will be instructed to report the level of pain
sensation to a point along this line, with the scores
ranging from 0 to 10 and obtained by measuring the
distance between the end anchored by the term
without pain and the point marked by the partici-
pant [29]. Additional analysis will include changes
from randomization to the end of withdrawal (week
10) in an adapted Portuguese version of the McGill
Pain Questionnaire (McPQ) [30].
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A digital algometer (DD-200; Instrutherm, Sao Paulo,
Brazil) will be used to evaluate pain sensibility through
the application of pressure. The algometer will be posi-
tioned to read specific FM tender points and TMD
joints using the rubber tip measuring 1 cm2 in direct
contact with the skin. A gradually increasing pressure
will be applied to all points until the patient reports feel-
ing pain, at which point the researcher will stop applying
pressure and display values will be recorded. The proce-
dures will be performed only once to each point, and a
30-s rest period will be given between readings [29].
Fibromyalgia symptoms and quality of life
Outcome parameters will be evaluated with the FIQ.
The FIQ is a multidimensional instrument developed to
assess several FM symptoms (pain, fatigue, stiffness, ten-
derness, sleep disorders, depressed mood, anxiousness,
problems with memory, imbalance, sensitivity to non-
painful stimuli, and performing daily tasks) [29]. The
Medical Outcomes Study 36-item Short Form Health
Survey (SF-36) will also be used [29].
Salivary serotonin
Concentration of serotonin in the saliva is relevant to
nociception and the pathogenesis of chronic pain syn-
dromes seen in FM [31]. Thus, mean serotonin changes
from randomization to the end of withdrawal will be
evaluated in 25-μl salivary samples by using a competi-
tive enzyme-linked immunosorbent assay (ELISA) ac-
cording to the manufacturer’s instructions (Human
Serotonin ST ELISA Kit; MyBioSource, San Diego, CA,
USA). The samples will be collected with cotton swabs
into plastic tubes without any stimulation and frozen
(−80 °C). Patients will be instructed to rinse their
mouths with water and not to eat or drink 30 min before
the samples are collected. The ELISA plates will be read
with a SpectraMax Plus 384 spectrophotometer (Mo-
lecular Dynamics, Sunnyvale, CA, USA) at a wavelength
of 400 nm [31].
Statistical analysis
Pain will be the primary endpoint and will be deter-
mined using a VAS, an algometer, the FIQ, and the
McPQ. Quality of life as assessed by SF-36, salivary sero-
tonin level, and overall parameters of pain will be sec-
ondary endpoints. Statistical analysis will be performed
using IBM SPSS software (version 13.0; IBM, Armonk,
NY, USA), and a two-sided P value <0.05 will be consid-
ered significant. The intragroup and intergroup compar-
isons will be carried out with two-way repeated-
measures analysis of variance with post hoc Bonferroni
correction or the Kruskal-Wallis test with a post hoc Dunn
test. The choice of tests will be based on the distribution(normal or non-normal) of the data by the Shapiro–Wilk
test. For categorical data, χ2 statistics will be used.
Ethical approval
The ethics committee of the Nove de Julho University
(Sao Paulo, Brazil) reviewed and approved this study
protocol (protocol number 419.828/2013). The trial was
conceived and will be conducted according to the princi-
ples set forth in the Declaration of Helsinki [32]. All pa-
tients will be requested to provide written informed
consent prior to randomization, using standard forms.
Patients may withdraw from the study at any time with-
out penalty. Our standpoint is that any intervention has
beneficial effect. It is an ethical issue in which the con-
trol group knows the positive results of the study.
Therefore, the control group will be given the opportun-
ity to receive intervention after the end of the trial. The
trial is registered at ClinicalTrials.gov under the number
NCT02279225 (27 October 2014).
Discussion
The findings this trial are predicted to offer evidence re-
garding the role of phototherapy and exercise training as
well as a combined intervention in a multimodal manage-
ment program for patients with FM and TMD. This is a
target population because TMD prevalence is higher in pa-
tients with FM [28]. Pain is a the main symptom of these
conditions [33–35], and it limits the patient’s activities of
daily living, such as walking, carrying objects, occupational,
eating, talking, yawning, and smiling, as well as a worsened
in quality of life [35, 36]. Moreover, pain is associated to
sleep disturbances, fatigue, and mood and memory disor-
ders [36, 37]. Hence, we consider that pain may represent
the main endpoint in the EXTRAPHOTO trial.
It has been proposed that chronic pain disorders are
driven mainly by alterations in the central nervous system
in which serotonin is considered the most important
neurotransmitter that modulates endogenous mechanisms
[38]. Because several studies have shown that serotoniner-
gic dysfunction can mediate the pathophysiology of FM
and TMD [38, 39], salivary serotonin level will represent a
secondary endpoint in the EXTRAPHOTO trial. To the
best of our knowledge, no previous randomized controlled
trial has evaluated whether phototherapy and/or exercise
training can modulate endogenous serotonin in patients
with FM and TMD [40].
The EXTRAPHOTO trial is the first randomized con-
trolled study evaluating the role of phototherapy, exer-
cise training, and a combination of these interventions
for chronic pain in patients with FM and TMD. In fact,
the results of this trial will provide valuable clinical evi-
dence for objective assessment of the potential benefits
and risks of procedures. The results will be published
after the trial is completed.
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The proposed study is presently under development, and
individuals are being allocated in the experimental
groups.
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